IGFBP3 and breast carcinoma: It has also been shown that the expression of KLK11 in breast cancer contributes significantly to the progression of cancer by increasing the bioavailability of IGF through degradation of IGFBP-3[30], and extremely significant expression of KLK11 was observed in patients with breast cancer grades I and II compared to III.